Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma
出版年份 2021 全文链接
标题
Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma
作者
关键词
-
出版物
Cancers
Volume 13, Issue 24, Pages 6342
出版商
MDPI AG
发表日期
2021-12-20
DOI
10.3390/cancers13246342
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
- (2021) Amod A. Sarnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibition promotes anti-tumor immunity through the induction of T cell memory
- (2021) Emily J Lelliott et al. Cancer Discovery
- Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
- (2021) Troels Holz Borch et al. Journal for ImmunoTherapy of Cancer
- Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
- (2021) Kedar Kirtane et al. Journal for ImmunoTherapy of Cancer
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
- (2020) Jenny H. Lee et al. Nature Communications
- Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
- (2020) Emily J. Lelliott et al. Cancer Immunology Research
- A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy
- (2019) Emily J. Lelliott et al. Scientific Reports
- BRAF targeting sensitizes resistant melanoma to cytotoxic T cells
- (2019) Cigdem Atay et al. CLINICAL CANCER RESEARCH
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enterotoxins can support CAR T cells against solid tumors
- (2019) Bianca von Scheidt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance
- (2018) Claire A. Martin et al. INTERNATIONAL JOURNAL OF CANCER
- Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
- (2018) Xin Jin et al. MOLECULAR CELL
- Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
- (2017) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma
- (2016) Drew C. Deniger et al. CLINICAL CANCER RESEARCH
- Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition
- (2016) Peter Kar Han Lau et al. CURRENT OPINION IN IMMUNOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
- (2015) S. D. Bradley et al. Cancer Immunology Research
- Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
- (2014) Richard J. Young et al. Pigment Cell & Melanoma Research
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
- (2013) Deborah A. Knight et al. JOURNAL OF CLINICAL INVESTIGATION
- Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
- (2013) Bishu Sapkota et al. OncoImmunology
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- (2012) Richard C. Koya et al. CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now